Table 1.

Patient characteristics

Characteristicn (%)
Total patients50
Menopause
 No32
 Yes16
 Unknown2
T-stage (tumor size obtained with breast ultrasound and/or mammogram)
 T16
 T234
 T34
 T46
AJCC clinical stagea
 IIA13
 IIB21
 IIIA7
 IIIB2
 IIIC7
Tumor grading
 Grade I0
 Grade II7
 Grade III39
 Missing4
Architectural differentiation
 Score I0
 Score II7
 Score III38
 Missing5
Nuclear pleomorphism
 Score I0
 Score II4
 Score III41
 Missing5
Number of mitoses
 Score I3
 Score II9
 Score III33
 Missing5
Ki-67 tumor expression (%)
 Mean ± SD67 ± 18
 Median70
 Missing7
EGFR expression
 Negative26
 Positive20
 Missing4
AR status
 Negative38
 Positive (>10%)8
 Missing4
CK5/6 expression
 Negative12
 Positive34
 Missing4
Phenotype
 Basal-like39
 Non–basal-like7
 Missing4
Chemotherapy regimen
 6 courses of FEC1009
 3 courses of FEC100 followed by 3 courses of docetaxel41
Surgery
 Breast-conserving surgery37
 Mastectomy13
pCR (ypT0/is ypN0)b
 Yes21
 No29
  • aClinical stage according to the seventh edition of the American Joint Committee on Cancer (AJCC) staging manual (tumor size assessed with ultrasound scan, lymph node involvement, and metastasis assessed both with ultrasound scan and with FDG-PET, metastasis status assessed with FDG-PET).

  • bpCR is defined as ypT0/is ypN0: no invasive residual in the breast and nodes; in situ breast residuals allowed.